DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR MEKINIST
» See Plans and Pricing
All Clinical Trials for Mekinist
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01438554 | Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma | Active, not recruiting | GlaxoSmithKline | Phase 1 | 2011-10-01 | The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study. |
| NCT01438554 | Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma | Active, not recruiting | National Comprehensive Cancer Network | Phase 1 | 2011-10-01 | The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study. |
| NCT01438554 | Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma | Active, not recruiting | Sidney Kimmel Comprehensive Cancer Center | Phase 1 | 2011-10-01 | The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study. |
| NCT01553851 | GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer | Completed | National Comprehensive Cancer Network | Phase 2 | 2013-02-01 | This phase II trial studies how trametinib effects tumor cells in patients with oral cavity squamous cell carcinoma that can be removed by surgery. Trametinib may shrink the tumor by blocking an enzyme pathway needed for cell growth. |
| NCT01553851 | GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer | Completed | Washington University School of Medicine | Phase 2 | 2013-02-01 | This phase II trial studies how trametinib effects tumor cells in patients with oral cavity squamous cell carcinoma that can be removed by surgery. Trametinib may shrink the tumor by blocking an enzyme pathway needed for cell growth. |
| NCT01827384 | Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors | Recruiting | National Cancer Institute (NCI) | N/A | 2013-12-01 | This randomized pilot phase II trial studies molecular profiling-based targeted therapy in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment. WEE1 inhibitor MK-1775, everolimus, and trametinib are drugs that each target a specific variation in tumors by blocking different proteins needed for cell growth. Veliparib blocks an enzyme that helps repair deoxyribonucleic acid (DNA) damaged by chemotherapy, which may help chemotherapy drugs work better. It is not yet known whether testing patients for variations in their tumor and assigning treatment targeting the variation is more effective than standard non-targeted therapy in treating advanced solid tumors. |
| NCT01902173 | Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer | Suspended | GlaxoSmithKline | Phase 1/Phase 2 | 2013-07-01 | This phase I/II trial studies the side effects and the best dose of Akt inhibitor GSK2141795 when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IIIC-IV cancer. Akt inhibitor GSK2141795, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving Akt inhibitor GSK2141795 with dabrafenib and trametinib may be a better treatment for cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Mekinist
Condition Name
Clinical Trial Locations for Mekinist
Trials by Country
Clinical Trial Progress for Mekinist
Clinical Trial Phase
Clinical Trial Sponsors for Mekinist
Sponsor Name
